Species level identification of microorganisms is vital in combating the vast range of pathogens that infect humans. Bacteria, yeast and mycobacteria, whether clinically common or rare, can cause serious harm when not identified and treated quickly. Increasingly prevalent conditions, such as sepsis or multi-drug resistant (MDR) microorganism infections, pose a serious threat to hospitals and wider public health, requiring rapid, automated microbial identification and resistance testing solutions for the entire clinical workflow.
In parallel, effective hygiene management – especially in hospitals – is key to prevent healthcare associated infections as effectively as possible.
Bruker’s MALDI Biotyper®system has become the method of choice for routine microorganism identification in clinical laboratories worldwide. Based on Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass spectrometry (MALDI-TOF MS) technology, this microbial identification system is easy-to-use, fast, robust, high-throughput, cost-effective and highly efficient. Molecular diagnostics are another rapid solution for clinical microbiology, enabling real-time results in a culture-free workflow, for example in the case of fungal infections. Bruker’s expertise in antimicrobial susceptibility testing (AST) and mycobacteria identification provides a complete solution, continuously innovating to address today’s global diseases.